|
[1]
|
Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an
In Vitro
Pharmacokinetic/Pharmacodynamic Model That Correlates with Clinical Response to Caspofungin Therapy: Is There a Place for Dose Optimization?
Antimicrobial Agents and Chemotherapy,
2021
DOI:10.1128/AAC.01618-20
|
|
|
|
|
[2]
|
Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta‐analysis
Journal of Clinical Pharmacy and Therapeutics,
2020
DOI:10.1111/jcpt.13211
|
|
|
|
|
[3]
|
Comparative pharmacokinetics of the three echinocandins in ICU patients
Journal of Antimicrobial Chemotherapy,
2020
DOI:10.1093/jac/dkaa265
|
|
|
|
|
[4]
|
Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients
Clinical Pharmacokinetics,
2017
DOI:10.1007/s40262-017-0509-5
|
|
|
|
|
[5]
|
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
Clinical Pharmacokinetics,
2017
DOI:10.1007/s40262-017-0578-5
|
|
|
|
|
[6]
|
Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction
European Journal of Drug Metabolism and Pharmacokinetics,
2015
DOI:10.1007/s13318-014-0204-y
|
|
|
|
|
[7]
|
Impact of special patient populations on the pharmacokinetics of echinocandins
Expert Review of Anti-infective Therapy,
2015
DOI:10.1586/14787210.2015.1028366
|
|
|
|
|
[8]
|
Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis
Journal of Antimicrobial Chemotherapy,
2015
DOI:10.1093/jac/dkv173
|
|
|
|
|
[9]
|
Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients
Antimicrobial Agents and Chemotherapy,
2015
DOI:10.1128/AAC.00623-15
|
|
|
|
|
[10]
|
Cardiac toxicity of the echinocandins: chance or cause and effect association?
Journal of Clinical Pharmacy and Therapeutics,
2014
DOI:10.1111/jcpt.12108
|
|
|
|